Supernus Current Ratio vs Net Income Analysis

SUPN Stock  USD 33.74  1.26  3.88%   
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Current Ratio and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Current Ratio vs Net Income

Current Ratio vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Current Ratio account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Supernus Pharmaceuticals' Current Ratio and Net Income is -0.36. Overlapping area represents the amount of variation of Current Ratio that can explain the historical movement of Net Income in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Current Ratio and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Ratio of Supernus Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Current Ratio i.e., Supernus Pharmaceuticals' Current Ratio and Net Income go up and down completely randomly.

Correlation Coefficient

-0.36
Relationship DirectionNegative 
Relationship StrengthInsignificant

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Supernus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Supernus Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 28th of March 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
 2021 2022 2023 2024 (projected)
Interest Expense23.4M7.1M2.4M2.3M
Depreciation And Amortization34.0M82.6M84.9M89.1M

Supernus Pharmaceuticals fundamental ratios Correlations

0.640.550.360.610.630.420.40.470.350.460.61-0.140.640.70.930.60.450.580.640.910.630.530.690.450.94
0.640.680.630.810.980.770.70.950.630.640.99-0.380.90.980.620.810.760.930.890.840.940.910.940.880.61
0.550.68-0.010.670.550.280.810.50.690.730.62-0.560.850.640.460.670.730.470.710.660.830.60.820.420.49
0.360.63-0.010.450.740.620.140.74-0.010.050.650.050.380.690.380.50.20.730.390.460.380.440.450.660.34
0.610.810.670.450.770.410.780.780.720.310.78-0.420.820.820.540.940.410.830.730.70.830.650.870.780.54
0.630.980.550.740.770.840.570.970.510.530.99-0.270.820.980.630.770.660.940.830.810.850.90.870.890.61
0.420.770.280.620.410.840.270.820.180.480.80.080.580.750.460.470.570.680.60.610.590.890.610.640.43
0.40.70.810.140.780.570.270.580.730.510.66-0.60.850.620.290.830.650.580.660.540.850.610.810.530.31
0.470.950.50.740.780.970.820.580.520.440.96-0.280.780.940.460.750.60.940.790.690.820.880.830.920.43
0.350.630.69-0.010.720.510.180.730.520.540.62-0.710.660.570.30.570.590.620.780.50.780.570.70.690.33
0.460.640.730.050.310.530.480.510.440.540.6-0.270.750.580.470.360.910.350.680.640.740.640.70.350.51
0.610.990.620.650.780.990.80.660.960.620.6-0.380.860.980.60.770.750.940.890.820.910.920.910.90.59
-0.14-0.38-0.560.05-0.42-0.270.08-0.6-0.28-0.71-0.27-0.38-0.38-0.31-0.12-0.34-0.46-0.4-0.6-0.29-0.52-0.29-0.42-0.45-0.14
0.640.90.850.380.820.820.580.850.780.660.750.86-0.380.870.610.880.790.720.820.830.960.80.980.660.62
0.70.980.640.690.820.980.750.620.940.570.580.98-0.310.870.660.790.680.930.860.850.890.850.920.880.66
0.930.620.460.380.540.630.460.290.460.30.470.6-0.120.610.660.570.440.540.660.930.580.530.660.430.99
0.60.810.670.50.940.770.470.830.750.570.360.77-0.340.880.790.570.460.760.670.730.830.660.890.670.56
0.450.760.730.20.410.660.570.650.60.590.910.75-0.460.790.680.440.460.530.820.690.850.760.780.520.45
0.580.930.470.730.830.940.680.580.940.620.350.94-0.40.720.930.540.760.530.820.730.810.80.810.970.53
0.640.890.710.390.730.830.60.660.790.780.680.89-0.60.820.860.660.670.820.820.850.930.830.890.830.64
0.910.840.660.460.70.810.610.540.690.50.640.82-0.290.830.850.930.730.690.730.850.830.750.870.640.92
0.630.940.830.380.830.850.590.850.820.780.740.91-0.520.960.890.580.830.850.810.930.830.840.980.770.59
0.530.910.60.440.650.90.890.610.880.570.640.92-0.290.80.850.530.660.760.80.830.750.840.820.770.53
0.690.940.820.450.870.870.610.810.830.70.70.91-0.420.980.920.660.890.780.810.890.870.980.820.750.66
0.450.880.420.660.780.890.640.530.920.690.350.9-0.450.660.880.430.670.520.970.830.640.770.770.750.42
0.940.610.490.340.540.610.430.310.430.330.510.59-0.140.620.660.990.560.450.530.640.920.590.530.660.42
Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding53.8M53.7M54.4M61.7M55.5M42.6M
Total Assets1.2B1.5B1.7B1.7B1.4B1.5B
Short Long Term Debt Total375.6M390.3M420.6M438.0M41.5M39.5M
Other Current Liab3.2M40.0M65.0M139.8M279.9M293.9M
Total Current Liabilities160.6M245.1M315.4M688.0M290.2M154.7M
Total Stockholder Equity595.4M744.9M815.9M886.2M921.5M967.6M
Property Plant And Equipment Net38.3M37.8M17.0M15.2M42.5M44.7M
Net Debt194.2M101.7M217.1M344.8M(33.5M)(31.9M)
Retained Earnings199.5M326.5M379.9M481.2M482.6M506.7M
Accounts Payable10.1M78.9M117.7M96.3M2.0M1.9M
Cash181.4M288.6M203.4M93.1M75.1M116.1M
Non Current Assets Total687.6M873.7M1.1B968.4M915.9M961.7M
Non Currrent Assets Other615K8.0M(36.1M)(10.0M)8.5M8.9M
Cash And Short Term Investments347.1M422.5M339.7M461.3M254.9M201.2M
Net Receivables87.3M140.9M148.9M165.5M144.2M151.4M
Common Stock Total Equity51K52K53K54K62.1K40.8K
Short Term Investments165.7M133.9M136.2M368.2M179.8M98.1M
Liabilities And Stockholders Equity1.2B1.5B1.7B1.7B1.4B1.5B
Non Current Liabilities Total404.3M514.1M557.9M128.3M197.3M179.2M
Inventory26.6M48.3M86.0M91.5M77.4M81.3M
Other Current Assets11.6M18.7M27.0M15.8M16.7M8.5M
Other Stockholder Equity388.4M409.3M434.3M408.1M439.5M279.8M
Total Liab564.9M759.2M873.3M816.3M487.5M333.9M
Property Plant And Equipment Gross38.3M37.8M33.4M28.2M28.9M30.4M
Total Current Assets472.6M630.4M601.6M734.2M493.1M305.3M
Accumulated Other Comprehensive Income7.4M9.0M1.5M(3.2M)(593K)(563.4K)
Intangible Assets24.8M442.3M784.7M702.5M599.9M629.9M
Common Stock51K52K53K54K55K42.0K
Other Liab28.7M123.8M137.4M92.3M106.2M111.5M
Other Assets32.7M259.7M13.9M10.9M12.5M11.9M
Long Term Debt329.5M345.2M361.8M379.3M436.1M457.9M
Property Plant Equipment17.1M37.8M52.3M44.1M50.7M53.2M
Net Tangible Assets570.6M302.6M(86.4M)66.7M76.7M72.9M
Good Will24.8M77.9M117.5M117.0M134.6M141.3M
Retained Earnings Total Equity199.5M326.5M379.9M481.2M553.4M581.1M
Capital Surpluse388.4M409.3M434.3M408.1M469.3M352.1M

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.